

Nephrology and Hypertension

Division Photo



1st Row Seated: S. Goldstein, P. Devarajan; 2nd Row: M. Lo, M. Mitsnefes, K. Czech, B. Dixon, D. Claes, M. Bennett; 3rd Row: A. Kaddourah, J. Goebel, L. Patterson, B. Laskin, R. Vandevoorde, J. Bissler. Not pictured: E. Abraham, D. Hooper, E. Jackson, R. Malatesta-Muncher, E. Nehus

Division Data Summary

Research and Training Details

Number of Faculty	13
Number of Research Fellows	6
Number of Support Personnel	7
Direct Annual Grant Support	\$1,004,162
Direct Annual Industry Support	\$62,336
Peer Reviewed Publications	34

Clinical Activities and Training

Number of Clinical Fellows	6
Inpatient Encounters	3945
Outpatient Encounters	2,869

Faculty Members

Prasad Devarajan, MD, Professor
John J. Bissler, MD, Professor
Kimberly Czech, MD, PhD, Instructor
Bradley P. Dixon, MD, Assistant Professor
Jens Goebel, MD, Associate Professor Clinical
Elizabeth Jackson, MD, Associate Professor Clinical
Paul McEnery, MD, Professor Emeritus
Mark Mitsnefes, MD, Associate Professor Clinical

Larry Patterson, MD, Research Associate Professor

C. Frederic Strife, MD, Professor

Trainees

- Donald Weaver, MD, PL-3,
- Amy Wilson, MD, PL-3,
- David Hooper, MD, PL-2,
- Elizabeth Abraham, MD, PL-2,
- Benjamin Laskin, MD, PL-1,
- Megan Lo, MD, PL-1,

Significant Accomplishments

Biomarker Core for personalized kidney care

The diagnosis of kidney disease can be painfully slow, but we are helping accelerate it with a new lab, the Cincinnati Children's Biomarker Core. Through the use of cutting-edge biomarker technology, we are making kidney disease diagnosis faster and more personalized than ever before.

The Biomarker Core grew out of work led by division director Prasad Devarajan, MD, which uncovered a panel of urine and blood biomarkers that accurately assess the presence, risk and severity of acute and chronic kidney disease. Core director Michael Bennett, PhD, uses these biomarkers to provide a range of clinical and lab services to investigators and clinicians across the globe. We provide everything from consultation on biomarker discovery to assays of patient samples from clinicians. To date, we've established more than 20 collaborative research projects, and the Biomarker Core has performed more than 25,000 assays on patient samples.

Center for Acute Care Nephrology

This year, acute kidney injury was responsible for more than 4 million deaths worldwide. To develop best practices of care for patients with, or at risk of, acute kidney injury, we launched the Cincinnati Children's Center for Acute Care Nephrology, a collaborative effort between Nephrology, the Heart Institute and Critical Care.

Stuart Goldstein, MD, expert in the field of pediatric acute kidney injury, directs the center. Its mission is to transform clinical care, education and nephrology research at Cincinnati Children's and for those who refer to us. The center provides advanced dialysis and pheresis care and conducts basic, clinical and translational research projects; we explore the identification, treatment and prevention of acute kidney injury in a variety of clinical situations. The center will also provide specialized fellowship training in critical care nephrology.

Kidney Transplant Center

Since starting the Kidney Transplant Center at Cincinnati Children's in 1965, we have performed nearly 500 pediatric kidney transplants. We've seen an explosion in activity in recent years, largely due to the efforts of clinical director Jens Goebel, MD. During FY 2010, we performed 24 kidney transplants, an all-time record for our program, placing us within the top five busiest pediatric kidney transplant centers in the country.

Along with the quantity of transplants, we're working to maintain high quality in our care practices. We established novel protocols to optimize the care of children with the most complex malformations, diseases and complications, such as recurrence of the primary disease, antibody-mediated rejection and BK virus nephropathy.

Division Publications

1. :

Grants, Contracts, and Industry Agreements

Grant and Contract Awards

Annual Direct / Project Period Direct

Bissler, J

Tuberous Sclerosis Complex Natural History Study

Department of Defense Army

W81XWH-06-1-0538

05/01/06 - 04/30/11

\$45,529 / \$546,352

Czech, K

Altered Gene Expression Using Microarray in Focal Segmental Glomerulosclerosis

National Institutes of Health

F32 DK 079545

07/05/07 - 07/04/10

\$59,402 / \$177,174

Devarajan, P**Implications of the Ask1/Jnk Pathway in Arf**

National Institutes of Health

R01 DK 069749

04/01/05 - 03/31/10

\$204,428 / \$1,052,286

Research Training in Pediatric Nephrology

National Institutes of Health

T32 DK 007695

07/01/07 - 06/30/12

\$109,163 / \$343,043

Novel Biomarkers in Cardiac Surgery to Detect Acute Kidney Injury

Yale University School of Medicine (National Institutes of Health)

R01 HL 085757

05/01/07 - 01/31/11

\$73,170 / \$228,479

Progression of Acute Kidney Injury to Chronic Kidney Disease

Yale University School of Medicine (National Institutes of Health)

U01 DK 082185

09/01/08 - 06/30/13

\$37,980 / \$108,357

Early Prediction of Lupus Nephritis using Advanced Proteomics

Department of Defense

W81XWH-07-1-0322

06/01/2007 - 05/31/2010

\$211,400 / \$850,161

Goebel, J**Health and Literacy in Child and Adult Assessment-Pediat**

University of North Carolina

08/01/2008 - 07/31/2010

\$1,074 / \$2,649

Chronic Renal Insufficiency in NAPRTCS Patients

Children's Mercy Hospital (National Institutes of Health)

U01 DK 066143

08/01/09 - 07/31/10

\$10,200 / \$10,200

Mitsnefes, M**Adiponectin and Cardiovascular Disease in the CKiD Children**

National Institutes of Health

R01 DK076957

09/01/2007 - 08/31/2010

\$188,526 / \$519,000

Siroky, B**The Role of Primary Cilia in Regulating Mammalian Target of Rapamycin Signaling**

PKD Foundation

07/01/2008 - 06/30/2010

\$45,000 / \$90,455

Environmental Carcinogenesis and Mutagenesis

University of Cincinnati

T32 ES 007250

04/01/2010 - 06/30/2010

\$18,290 / \$18,290

Current Year Direct**\$1,004,162****Industry Contracts****Bissler, J**

Novartis Pharmaceuticals

\$ 51,937

Strife, CF

Amgen, Inc.

\$ 10,399

Current Year Direct Receipts**\$62,336****Total \$1,066,499**